Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alnylam Pharma (ALNY – Research Report), Biogen (BIIB – Research Report) and Pacira Pharmaceuticals (PCRX – Research Report).
Alnylam Pharma (ALNY)
In a report released yesterday, Zhiqiang Shu from Berenberg Bank maintained a Hold rating on Alnylam Pharma, with a price target of $154.00. The company’s shares closed last Thursday at $151.67.
According to TipRanks.com, Shu has 0 stars on 0-5 stars ranking scale with an average return of
Alnylam Pharma has an analyst consensus of Strong Buy, with a price target consensus of $215.35.
See the top stocks recommended by analysts >>
Biogen (BIIB)
In a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on Biogen, with a price target of $363.00. The company’s shares closed last Thursday at $239.66, close to its 52-week low of $221.72.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of
Currently, the analyst consensus on Biogen is a Moderate Buy with an average price target of $330.75, implying a 37.6% upside from current levels. In a report issued on December 22, Oppenheimer also maintained a Buy rating on the stock with a $350.00 price target.
Pacira Pharmaceuticals (PCRX)
Needham analyst Serge Belanger maintained a Buy rating on Pacira Pharmaceuticals today and set a price target of $84.00. The company’s shares closed last Thursday at $61.26.
According to TipRanks.com, Belanger is a 2-star analyst with an average return of
Pacira Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $81.50, implying a 36.0% upside from current levels. In a report issued on January 3, J.P. Morgan also initiated coverage with a Buy rating on the stock with a $83.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ALNY: